Professor, Radiology, University of Washington School of Medicine
Radiology
Dr. David A. Mankoff, MD
|
|
Give Review
Doctor David A. Mankoff, MD works in the field of Radiology. He studied medicine at Perelman School of Medicine at the University of Pennsylvania. He received 2 awards: "CMS Meaningful Use Stage 1 Certification" and "Whos Who in Medicine and Healthcare". David A. Mankoff, MD is a published doctor and has 101 publications published. The lastest was: 'Management of Differentiated Thyroid Cancer in Children: Focus on the American Thyroid Association Pediatric Guidelines.'
Publications
- Management of Differentiated Thyroid Cancer in Children: Focus on the American Thyroid Association Pediatric Guidelines.
- Novel Strategies for Breast Cancer Imaging: New Imaging Agents to Guide Treatment.
- Introduction and Overview.
- 18F-FDG PET/CT for Staging and Restaging of Breast Cancer.
- Temporal Heterogeneity of Estrogen Receptor Expression in Bone-Dominant Breast Cancer: 18F-Fluoroestradiol PET Imaging Shows Return of ER Expression.
- Technology for Innovation in Radiation Oncology.
- Multicenter clinical trials using 18F-FDG PET to measure early oncology therapy response: Effects of injection-to-acquisition time variability on required sample size.
- Castration-Resistant Prostate Cancer Bone Metastasis Response Measured by 18F-Fluoride PET After Treatment with Dasatinib and Correlation with Progression-Free Surviva...
- Use of Standardized Uptake Value Ratios Decreases Interreader Variability of [18F] Florbetapir PET Brain Scan Interpretation.
- Choosing a single target as a biomarker or therapeutic using radioactive probes.
- The contribution of physics to Nuclear Medicine: physicians' perspective on future directions.
- ACR Appropriateness Criteria Stage I Breast Cancer: Initial Workup and Surveillance for Local Recurrence and Distant Metastases in Asymptomatic Women.
- Role of PET quantitation in the monitoring of cancer response to treatment: Review of approaches and human clinical trials.
- VOXEL-LEVEL MAPPING OF TRACER KINETICS IN PET STUDIES: A STATISTICAL APPROACH EMPHASIZING TISSUE LIFE TABLES.
- PET/CT imaging in cancer: Current applications and future directions.
- Activity of P-Glycoprotein, a β-Amyloid Transporter at the Blood-Brain Barrier, Is Compromised in Patients with Mild Alzheimer Disease.
- Molecular Imaging Biomarkers for Oncology Clinical Trials.
- A Virtual Clinical Trial of FDG-PET Imaging of Breast Cancer: Effect of Variability on Response Assessment.
- Preoperative MRI improves prediction of extensive occult axillary lymph node metastases in breast cancer patients with a positive sentinel lymph node biopsy.
- A Phase 2 Study of 16α-[(18)F]-fluoro-17β-estradiol Positron Emission Tomography (FES-PET) as a Marker of Hormone Sensitivity in Metastatic Breast Cancer (MBC).
- ACR Appropriateness Criteria Palpable Breast Masses.
- 131I Therapy Using rhTSH Stimulation and Dosimetry in Metastatic Malignant Struma Ovarii.
- Breast Cancer, Version 3.2013.
- Modeling Cyclosporine A Inhibition of the Distribution of a P-Glycoprotein PET Ligand, 11C-Verapamil, into the Maternal Brain and Fetal Liver of the Pregnant Nonhuman ...
- ACR Appropriateness Criteria Breast Cancer Screening.
- Quantitative assessment of dynamic PET imaging data in cancer imaging.
- Early experiences in establishing a regional quantitative imaging network for PET/CT clinical trials.
- ACR Appropriateness Criteria® stage I breast carcinoma.
- 18FFluorodeoxyglucose Positron Emission Tomography-Computed Tomography in Breast Cancer: When... and When Not?
- Advances in molecular imaging for breast cancer detection and characterization.
- Design Considerations for using PET as a Response Measure in Single Site and Multicenter Clinical Trials.
- Between-Patient and Within-Patient (Site-to-Site) Variability in Estrogen Receptor Binding, Measured In Vivo by 18F-Fluoroestradiol PET.
- Fluoroestradiol Positron Emission Tomography Reveals Differences in Pharmacodynamics of Aromatase Inhibitors, Tamoxifen, and Fulvestrant in Patients with Metastatic Br...
- ABNM Celebrates 40th Anniversary.
- ABNM Position Statement: Nuclear Medicine Professional Competency and Scope of Practice.
- PET Tumor Metabolism in Locally Advanced Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy: Value of Static versus Kinetic Measures of Fluorodeoxyglucose Uptake.
- Multiagent PET for risk characterization in sarcoma.
- C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases: relative findings and response to therapy.
- Invasive breast cancer.
- Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functiona...
- Breast cancer and hormonal stimulation: is glycolysis the first sign of response?
- Association between serial dynamic contrast-enhanced MRI and dynamic 18F-FDG PET measures in patients undergoing neoadjuvant chemotherapy for locally advanced breast c...
- Tumor metabolism and blood flow as assessed by positron emission tomography varies by tumor subtype in locally advanced breast cancer.
- Kinetic analysis of 18F-fluoride PET images of breast cancer bone metastases.
- Imaging tumor phenotype: 1 plus 1 is more than 2.
- Blood flow-metabolism mismatch: good for the tumor, bad for the patient.
- Usefulness of 123I-MIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma: results from a pros...
- Imaging of cyclosporine inhibition of P-glycoprotein activity using 11C-verapamil in the brain: studies of healthy humans.
- Disease Restaging and Diagnosis of Recurrent and Metastatic Disease Following Primary Therapy with FDG-PET Imaging.
- The role of radiotracer imaging in the diagnosis and management of patients with breast cancer: part 2--response to therapy, other indications, and future directions.
- Simultaneous PET imaging of P-glycoprotein inhibition in multiple tissues in the pregnant nonhuman primate.
- The role of radiotracer imaging in the diagnosis and management of patients with breast cancer: part 1--overview, detection, and staging.
- Proliferation imaging to measure early cancer response to targeted therapy.
- Metabolic and vascular features of dynamic contrast-enhanced breast magnetic resonance imaging and (15)O-water positron emission tomography blood flow in breast cancer.
- Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced br...
- Tumor receptor imaging.
- Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol.
- Locally advanced and inflammatory breast cancer.
- Positron emission tomography-guided conformal fast neutron therapy for glioblastoma multiforme.
- 18F-Fluoroestradiol.
- Internal mammary nodal chain drainage is a prognostic indicator in axillary node-positive breast cancer.
- FDG PET, PET/CT, and breast cancer imaging.
- Tumor-specific positron emission tomography imaging in patients: [18F] fluorodeoxyglucose and beyond.
- Gastric linitis plastica from metastatic breast carcinoma: FDG and FES PET appearances.
- Dynamic and static approaches to quantifying 18F-FDG uptake for measuring cancer response to therapy, including the effect of granulocyte CSF.
- Beyond detection: novel applications for PET imaging to guide cancer therapy.
- A definition of molecular imaging.
- NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer.
- Molecular imaging research in the outcomes era: measuring outcomes for individualized cancer therapy.
- Monitoring targeted therapy: is fluorodeoxylucose uptake a marker of early response?
- Kinetic analysis of 3'-deoxy-3'-18F-fluorothymidine in patients with gliomas.
- Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer.
- Verapamil P-glycoprotein transport across the rat blood-brain barrier: cyclosporine, a concentration inhibition analysis, and comparison with human data.
- Medullary thyroid cancer: options for systemic therapy of metastatic disease?
- Clinical utility of somatostatin receptor scintigraphic imaging (octreoscan) in esthesioneuroblastoma: a case study and survey of somatostatin receptor subtype express...
- Current and future use of positron emission tomography (PET) in breast cancer.
- [F-18]-fluorodeoxyglucose positron emission tomography for targeting radiation dose escalation for patients with glioblastoma multiforme: clinical outcomes and pattern...
- [11C]metahydroxyephedrine and [18F]fluorodeoxyglucose positron emission tomography improve clinical decision making in suspected pheochromocytoma.
- The progress and promise of molecular imaging probes in oncologic drug development.
- Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography.
- Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development.
- Evolving role of positron emission tomography in breast cancer imaging.
- Residual tumor uptake of [99mTc]-sestamibi after neoadjuvant chemotherapy for locally advanced breast carcinoma predicts survival.
- Kinetic modeling of 3'-deoxy-3'-fluorothymidine in somatic tumors: mathematical studies.
- Kinetic analysis of 3'-deoxy-3'-fluorothymidine PET studies: validation studies in patients with lung cancer.
- PET imaging of cellular proliferation.
- 18F-FDG kinetics in locally advanced breast cancer: correlation with tumor blood flow and changes in response to neoadjuvant chemotherapy.
- Combined use of MRI and PET to monitor response and assess residual disease for locally advanced breast cancer treated with neoadjuvant chemotherapy.
- 18F-FDG PET of gliomas at delayed intervals: improved distinction between tumor and normal gray matter.
- Comparison of different quantitative approaches to 18F-fluoride PET scans.
- Evaluation of the internal mammary lymph nodes by FDG-PET in locally advanced breast cancer (LABC).
- Current and future uses of positron emission tomography in breast cancer imaging.
- Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging.
- Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy.
- Positron emission tomography imaging of brain tumors.
- 18F-Fluorothymidine radiation dosimetry in human PET imaging studies.
- Quantitative positron emission tomography imaging to measure tumor response to therapy: what is the best method?
- SUV varies with time after injection in (18)F-FDG PET of breast cancer: characterization and method to adjust for time differences.
- Are we ready for dedicated breast imaging approaches?
- Volumetric analysis of 18F-FDG PET in glioblastoma multiforme: prognostic information and possible role in definition of target volumes in radiation dose escalation.
Schools
Perelman School of Medicine University of Pennsylvania
University Wash Affil Hosps
Doctors Specialties
- Internal Medicine
- Nuclear Medicine
- Radiology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Personal Choice PPO
- Regional Pref Network EPO
- Regional Pref Network HMO
- Regional Pref Network HMO+
- Regional Pref Network POS+
- Regional Pref Network PPO
- Bakery & Confectionary Union Plan
- Blue Card PPO
- Capital Blue Cross
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- CoreSource
- Coventry Health America PPO
- Coventry Health Care of Delaware PPO
- First Choice Health
- First Health (Coventry Health Care) PPO
- GEHA
- Group Health Cooperative
- Community Blue PPO
- Choice Care PPO
- Keystone Health Plan East HMO
- Mail Handlers Benefit Plan (MHBP)
- Medicaid
- Medicare MCR
- Meritain Health
- Molina
- MultiPlan PPO
- ODS Health Plan
- Freedom Plan
- Principal Life
- QualCare HMO
- QualCare PPO
- Preferred Provider Network PPN
- Uniform Medical Plan Classic
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- Oxford Liberty
- United Healthcare
- Wells Fargo Insurance
- Wisconsin Physicians Service
Awards
- CMS Meaningful Use Stage 1 Certification
- Whos Who in Medicine and Healthcare
Education
-
University of Washington -
Perelman School of Medicine at the University of Pennsylvania
Hospital
-
Hospital of the University of Pennsylvania -
Pennsylvania Hospital -
Penn Presbyterian Medical Center
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1497840896 |
| Last Name Of The Provider | MANKOFF |
| First Name Of The Provider | DAVID |
| View All |
Similar Doctors
|
|
Dr. Mary Frances Schubert, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Narainder K. Gupta, MB
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Bertram R. Russell Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Richard M. Ruderman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mable S. Jones, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Jane Sunoo, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Amit Maity, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Elaine L. Goldhammer, MD
This Doctor is OpenDoctor Recommended.
|